• Skip to main content
  • Skip to footer
cnb1439_3rs-project_nav-ad_v1
  • About us
  • News
  • Events
  • Careers
cn-bio-organ-on-a-chip-logo
  • Products
    • PhysioMimix® OOC Microphysiological Systems
    • Consumables
      • PhysioMimix® multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
    • Organ-on-a-chip models
    • Gut/Liver-on-a-chip
    • Lung-on-a-chip
    • Support packages
  • Applications
    • Disease modeling
    • Safety toxicology
    • ADME
  • Services
    • Non-Alcoholic Steatohepatitis
    • Drug-Induced Liver Injury
    • ADME
  • Technology
  • Resources
  • Company
    • About us
    • Events
    • News
    • Careers in Biotech
  • Contact us

Explore our solutions


PhysioMimix® is a suite of hardware, consumables and assay protocols that enable you to recreate complex human biology and accurately predict human drug responses.

PhysioMimix OOC

physiomimix-single-and-multi-organ-on-a-chip-systems
Learn more

Consumables

Multi-chip plates
3D validated cells
NASH-in-a-box
Bioavailability assay kit: Human 18
DILI assay kit: Human 24
Learn more

Models

Single-organ models
- Liver-on-a-chip model
- Lung-on-a-chip model
Multi-organ models
- Gut/Liver-on-a-chip models

Support packages

PhysioMimix® support packages

Discover the applications


Investigate the application areas that our PhysioMimix® products and services support

Learn more

Disease modeling

Metabolic dysfunction-associated steatohepatitis
Hepatitis B
Pulmonary infection
Learn more

Safety toxicology

Drug-induced liver injury
Immune-mediated liver injury
Learn more

ADME

Drug absorption
Drug metabolism
Drug bioavailability
Oligonucleotide delivery
Learn more

Studies as a service


Our team will work collaboratively with you to design a study around your research goals and generate actionable data within weeks

Learn more
icon-nash-1-150x150.png MASLD/MASH
icon-dili-tox-150x150.png Drug-induced liver injury
icon-adme-150x150.png ADME

Organ-on-a-Chip Resources

Resource type

Area of interest

Blogs

Resource image

Integrating In Silico Tools with Organ-on-a-Chip to advance ADME studies

Knowing a drug’s bioavailability during lead optimization is crucial as it directly influences dosing strategy, therapeutic efficacy, safety margins, and formulation design.

Videos and animations

Resource image

PhysioMimix® cross-species DILI CRS for enhanced IVIVE

Gain clarity, confidence, speed, and enhance your ethical responsibility by leveraging our cross-species Drug-induced liver injury assays (human, rat and dog) in your drug discovery or development workflow. Improve your in vitro to in vivo extrapolation (IVIVE) capabilities today via our DILI Contract Research Service.

Blogs

Resource image

CN Bio to participate in 3Rs Collaborative-lead project with FDA to build confidence in Liver MPS for DILI

Building Confidence in MPS for Regulatory Applications!

Brochures & Flyers

Resource image

PhysioMimix Bioavailability assay kit: Human 18 brochure

Modernize your workflow with the only in vitro bioavailability assessment tool on the market. Elevate your workflow with our all-in-one Bioavailability assay kit containing everything you need to recreate our human in vitro Gut/Liver-on-a-chip model and Bioavailability assay in your laboratory.

Brochures & Flyers

Resource image

PhysioMimix DILI assay kit: Human 24 brochure

Predict more complex, latent and immune-related hepatotoxicity in vitro. The PhysioMimix DILI assay kit contains everything you need to recreate our FDA-recognized assay in your own laboratory.

Webinars

Resource image

Harnessing Liver-on-a-chip models for drug safety

Webinar Series 8 Episode 2

Discover how to leverage human and animal Liver-on-a-chip (aka Liver microphysiological systems) in toxicology studies to enhance data translatability between preclinical testing and clinical applications.

Featuring industry experts from CN Bio and Bristol Myers Squibb.

Blogs

Resource image

Why the FDA animal testing phase-out for monoclonal antibodies?

In a groundbreaking press release on April 10th, 2025, the FDA announced its decision to phase out animal testing requirements for monoclonal antibodies, followed by other drugs – signaling a clear shift towards the use of more relevant human approaches for preclinical safety and toxicity testing.

Blogs

Resource image

Microphysiological systems for mAbs development: how do they address animal limitations?

Part two of our blog series exploring the FDA’s announcement to phase out the animal testing requirement for monoclonal antibodies (mAbs), and other drugs, in favor of human-relevant new approach methodologies (NAMs).

Articles

Resource image

How OOC can improve in vitro to in vivo translatability of preclinical data

Articles

Resource image

Organ-on-a-chip: a modernized toolbox for drug discovery challenges

Transforming drug discovery with a modernised toolbox. OOC is transforming accuracy, reducing failures, and accelerating new therapies.

Videos and animations

Resource image

PhysioMimix® bioavailability assay kit: Human 18 for simultaneous oral and intravenous in vitro bioavailability profiling

Discover the PhysioMimix® Bioavailability assay kit: Human 18, the only in vitro tool for profiling human bioavailability. This Organ-on-a-chip solution bridges the gap between in vitro and in vivo studies, enhancing preclinical ADME testing for CROs, pharma, and biotech. Explore how it streamlines lead optimization and improves drug development accuracy.

Videos and animations

Resource image

PhysioMimix® DILI assay kit: Human 24 for deeper mechanistic hepatotoxicity insights

Confidently predict DILI with PhysioMimix DILI assay kit: Human 24-accurate, human-relevant mechanistic hepatotoxicity insights to enhance drug safety in development

Speak to our experts

Request a meeting with one of our OOC experts to see how our products and services can support your studies

Request a meeting

Footer

CN Bio logo

332 Cambridge Science Park, Milton Road
Cambridge, CB4 0WN

UK: +44 (0) 1223 737 941

US: +1 415 523 4005

Privacy | Cookies | Regulatory | Accessibility
Website terms | Terms of sale

Product Recycling

©2025 CN Bio Innovations Ltd
Registered No. ‍06517359. VAT No. GB978184563

Latest news

  • Integrating In Silico Tools with Organ-on-a-Chip to advance ADME studies July 15, 2025
  • NIH to prioritize human-based research technologies & reduce animal use in research July 7, 2025
  • CN Bio to participate in 3Rs Collaborative-lead project with FDA to build confidence in Liver MPS for DILI June 25, 2025
Cyber Essentials Logo